Preclinical Antitumor Activity of Oral Silibinin-Meglumine in Combination with Erlotinib or Gefitinib in the Treatment of Erlotinib- and Gefitinib-Resistant EGFR-mutant NSCLC Mouse Xenografts.

Joaquim Bosch-Barrera,Silvia Cufi,Alejandro Vazquez-Martin,Cristina Oliveras-Ferraros,Bruna Corominas-Faja,Rosa Bonavia,Joana Visa,Begona Martin-Castillo,Enrique Barrajon-Catalan,Enric Carcereny,Vicente Micol,Javier A. Menendez

Journal of clinical oncology（2013）

引用 0|浏览17

暂无评分

摘要

e19003 Background: Silibinin (SLB), a bioactive flavonolignan isolated from the dried fruits of milk thistle (Silybum marianum), suppresses the resistance to erlotinib (ERL) caused by the EGFR T790...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要